Compare OCC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | ACHV |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.8M | 172.0M |
| IPO Year | 2001 | 2018 |
| Metric | OCC | ACHV |
|---|---|---|
| Price | $22.07 | $4.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 06-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,828,590.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $2.77 | $2.00 |
| 52 Week High | $27.98 | $6.16 |
| Indicator | OCC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 63.64 | 43.99 |
| Support Level | $6.38 | $4.09 |
| Resistance Level | $27.98 | $4.98 |
| Average True Range (ATR) | 3.30 | 0.42 |
| MACD | 0.36 | -0.05 |
| Stochastic Oscillator | 65.51 | 8.59 |
Optical Cable Corp manufactures a broad range of fiber optic and copper data communication cabling and connectivity solutions for the enterprise, wireless carrier, and specialty markets. The Company offers high quality products that operate as a system solution or integrate with other components, including fiber, copper, hybrid cabling, cabinets, racks, enclosures, and deployable solutions for enterprise networks, data centers, residential, campus, Passive Optical LAN installations, and customized applications in military, industrial, mining, petrochemical, renewable energy, and broadcast industries. It operates a single reportable segment covering the design, development, manufacture, and marketing of its cabling and connectivity solutions.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.